Semnan University of Medical Sciences

Research and Technology Vice Chancellor

Mohammadi, Ali Akbar and Sabet , Babak and Riazi , Hooman and Tavakkolian , Ahmad Reza and Mohammadi , Mohammad Kazem and Iranpak , Soraya (2010) The authors' reply. Iranian Journal of Medical Sciences. pp. 75-77.

[img] PDF
Download (187Kb)

    Abstract

    Dear Editor, I carefully read the letter about our manuscript that you sent to me.1 There were questions about our work, which I have answered below; 1- Randomization was done using random allocation software.2 2- I think there was a misunderstanding about table 3. Pain score before dressing means average score before all dressings in both groups, which was interpreted by Dr. Habibzadeh as the pain measured at the beginning of the study. Obviously when the time between dressings becomes longer, patients have less pain, and this is one of the advantages of amnion dressing. 3- Dr. Habibzadeh states that according to the article 32 of the Declaration of Helsinki code of ethics, a new intervention must be tested against the best current proven interventions. According to all textbooks related to “Burn”, the most effective and common treatment of burn in all burn centers is silver sulfadiazine.3-5 And almost always, in all controlled clinical trials in burn patients in the world, the control group receives silver sulfadiazine.6,7 On the other hand, all brands of synthetic dressing have many advantages and disadvantages. And no synthetic dressing has been suggested as the standard treatment in burn patients. Synthetic and biological dressings are alternatives to antimicrobial dressing. 5 Also, synthetic dressings are very expensive and are used in selected patients and rare circumstances, even in developed countries. For example; Integra (Integra lifeSciences corporation, USA) costs about 4500 US dollars for covering one percent of body surface area. It means that in a patient with 50% burn in his/her body surface area only one dressing with Integra would cost 225000 US dollars. With Acticoat (Smith&Nephew Healthcare Pvt.Ltd, USA), the cost is 2500 US dollars and with Biobrane (Smith&Nephew Healthcare Pvt.Ltd, USA) it is about 10000 US dollars.

    Item Type: Article
    Subjects: R Medicine > R Medicine (General)
    Divisions: Faculty of Medical Sciences > School of Medicine
    Depositing User: Mr Vahab Moshtaghi
    Date Deposited: 21 Dec 2016 03:22
    Last Modified: 21 Dec 2016 03:22
    URI: http://eprints.semums.ac.ir/id/eprint/661

    Actions (login required)

    View Item